ot-58
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03406611)
Timeline
Indications
Studied for
Mechanism of action
- Cystathionine beta-synthaseSupplementation
CBS supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS3G3529LUQ7 ↗
- ChEMBLCHEMBL4297799 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06431893 | Phase 3 | Apr 30, 2024 | Travere Therapeutics, Inc. |
| NCT06247085 | Phase 3 | Dec 28, 2023 | Travere Therapeutics, Inc. |
| NCT03406611 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | Neopharm |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2023 |
| Neopharm | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1